1 – 18 of 18
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
(
- Contribution to journal › Article
-
Mark
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy
(
- Contribution to journal › Article
-
Mark
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study
(
- Contribution to journal › Article
-
Mark
Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
(
- Contribution to journal › Article
-
Mark
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients : Design of the randomized controlled EVOLVD trial
(
- Contribution to journal › Article
- 2018
-
Mark
Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients
(
- Contribution to journal › Article
- 2017
-
Mark
Effect of Calcineurin Inhibitor-Free Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate after Heart Transplantation
(
- Contribution to journal › Article
-
Mark
Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up : Results of a randomized controlled trial (SCHEDULE)
(
- Contribution to journal › Article
- 2016
-
Mark
Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial.
(
- Contribution to journal › Article
-
Mark
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
(
- Contribution to journal › Article
- 2012
-
Mark
Long-term follow-up of lung and heart transplant recipients with pre-transplant malignancies
(
- Contribution to journal › Article
-
Mark
Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: The significance of baseline glomerular filtration rate
(
- Contribution to journal › Article
- 2011
-
Mark
Pregnancy in heart- and heart/lung recipients can be problematic
(
- Contribution to journal › Article
-
Mark
Effect of Everolimus Introduction on Cardiac Allograft Vasculopathy-Results of a Randomized, Multicenter Trial.
(
- Contribution to journal › Article
- 2010
-
Mark
Two-Year Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial.
(
- Contribution to journal › Article
-
Mark
Everolimus With Reduced Calcineurin Inhibitor in Thoracic Transplant Recipients With Renal Dysfunction: A Multicenter, Randomized Trial.
(
- Contribution to journal › Article